Showing results (11-20 of 28) with videos related to
Sort By:
Pageof 3
Clinical Lymphoma, Myeloma & Leukemia|November 15, 2019
Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple MyelomaAjai Chari, Dorothy Romanus, Antonio Palumbo, et al.The Oncologist|August 3, 2019
Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)Ajai Chari, Dorothy Romanus, Pronabesh DasMahapatra, et al.Cancer Medicine|September 24, 2022
Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplantSikander Ailawadhi, Augustina Ogbonnaya, Sharanya Murty, et al.Journal of Geriatric Oncology|October 24, 2017
The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapiesParameswaran Hari, Dorothy Romanus, Katarina Luptakova, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 26, 2009
Documentation of pain in comprehensive cancer centers in the United States: a preliminary analysisSharon M Weinstein, Dorothy Romanus, Eva M Lepisto, et al.Pharmacoeconomics - Open|October 13, 2019
Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple MyelomaRobert M Rifkin, Jill A Bell, Pronabesh DasMahapatra, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 8, 2011
Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003Lauren E Cipriano, Dorothy Romanus, Craig C Earle, et al.Future Oncology (London, England)|January 17, 2024
Development and validation of algorithms for identifying lines of therapy in multiple myeloma using real-world dataSikander Ailawadhi, Dorothy Romanus, Surbhi Shah, et al.Clinical Lymphoma, Myeloma & Leukemia|February 4, 2018
Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United StatesParameswaran Hari, Dorothy Romanus, Antonio Palumbo, et al.European Journal of Haematology|December 28, 2019
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trialFredrik Schjesvold, Hartmut Goldschmidt, Vladimir Maisnar, et al.Pageof 3